10242-36-1Relevant articles and documents
A Biocatalytic Synthesis of Heteroaromatic N-Oxides by Whole Cells of Escherichia coli Expressing the Multicomponent, Soluble Di-Iron Monooxygenase (SDIMO) PmlABCDEF
Petkevi?ius, Vytautas,Vaitekūnas, Justas,Taurait?, Daiva,Stankevi?iūt?, Jonita,?arlauskas, Jonas,??nas, Narimantas,Me?kys, Rolandas
, p. 2456 - 2465 (2019)
Aromatic N-oxides (ArN?OX) are desirable biologically active compounds with a potential for application in pharmacy and agriculture industries. As biocatalysis is making a great impact in organic synthesis, there is still a lack of efficient and convenient enzyme-based techniques for the production of aromatic N-oxides. In this study, a recombinant soluble di-iron monooxygenase (SDIMO) PmlABCDEF overexpressed in Escherichia coli was showed to produce various aromatic N-oxides. Out of 98 tested N-heterocycles, seventy were converted to the corresponding N-oxides without any side oxidation products. This whole-cell biocatalyst showed a high activity towards pyridines, pyrazines, and pyrimidines. It was also capable of oxidizing bulky N-heterocycles with two or even three aromatic rings. Being entirely biocatalytic, our approach provides an environmentally friendly and mild method for the production of aromatic N-oxides avoiding the use of strong oxidants, organometallic catalysts, undesirable solvents, or other environment unfriendly reagents. (Figure presented.).
METAL CHELATING COMPOUNDS FOR USE IN TREATING DISEASES
-
Page/Page column 25 ; 26, (2016/06/20)
The present invention relates to heterocyclic compounds for use in the treatment of diseases. In particular, the invention relates to heterocyclic compounds for use in the treatment of neurodegenerative diseases, such as Parkinson's or Alzheimer's disease, and methods of making and using the same. The heterocycle compounds contain at least one electronegative atom and comprise a hydroxyl group or substituted hydroxyl group at the 1-position and the carbon at the 2-position being a carbonyl group.
AMINONITRILES AS KYNURENINE PATHWAY INHIBITORS
-
Page/Page column 91, (2014/09/29)
The present application provides novel kynurenine pathway inhibitors and pharmaceutically acceptable salts and prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in regulating the kynurenine pathway and the activity of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase by administering a therapeutically effective amount of one or more of the compounds of formula (I) to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the kynurenine pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by immunosuppression, abnormal cellular proliferation and/or inflammation. In one embodiment, the disease is cancer. In another embodiment, the disease is a viral infection. In a further embodiment, the disease is depression.
